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developed for valuation. TTO interviews conducted with 400 respondents who were 
on average 36 (SD 13.5) yrs old; 39.2% male, 60.8% female; 46.4% White British; 
and 19% with COPD experience (self or others). Analyses are currently underway to 
ﬁt and validate a model using the above criteria. CONCLUSIONS: The EXACT-U is 
a condition-speciﬁc preference-based measure for use in clinical trials to evaluate 
change in utility of a COPD exacerbation patient from baseline through to 
resolution.
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OBJECTIVES: To ﬁnalise and establish the scoring algorithm of the 12-item “COPD           
and activities of daily living (ADL)” questionnaire, a tool speciﬁcally developed to 
help in the detection of handicap in COPD patients and determine the handicap level, 
thus optimising COPD management in the primary care setting. METHODS: The 
“COPD and ADL” questionnaire was developed and tested with patients and clini-
cians. It was included for ﬁnalisation and validation in a multi-centre, cross-sectional, 
observational study involving 100 French lung specialists. Patients with COPD stage 
II to IV according to the GOLD classiﬁcation were included. Finalisation of the ques-
tionnaire included: assessment of the quality of completion, veriﬁcation of the unidi-
mensionnality hypothesis using principal component analysis (PCA) and Rasch 
modelling (Partial Credit Model). RESULTS: Sixty lung specialists each included at      
least one patient. Two hundred and eighty two COPD patients were included, of 
whom 272 (96%) returned the “COPD and ADL” questionnaire. The quality of 
completion was very good (91% of questionnaires with no missing data), conﬁrming 
the good acceptability of the items. In the PCA, the ﬁrst factor explained 58% of the 
total variance, conﬁrming the a priori unidimensionnality hypothesis. The items 
“Impact of COPD on sexual life” and “Overall perception of handicap due to COPD” 
were considered for deletion from the score because they had high residual values in 
the Rasch analysis. After reduction to a 10-item score, the ﬁt of the Rasch model was 
acceptable (C2  27.452; p  0.599). CONCLUSIONS: The “COPD and ADL” ques-    
tionnaire is a short instrument assessing the handicap level among COPD patients, 
speciﬁcally designed as a clinical tool to contribute to patient management. The next 
step will be the validation of this instrument, including the assessment of its relation-
ships with other measures of health impairment in COPD patients.
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OBJECTIVES: The Global Initiative for Asthma (GINA) 2006 guidelines were revised 
in order to provide a new classiﬁcation for asthma based on disease control and to 
include new treatment strategies. The aim of the current study was to describe the 
opinion of patients, treated according to GINA 2006 guidelines, regarding their 
asthma control, treatment satisfaction and quality of life (QoL). METHODS: EPAG-
GELIA was a descriptive, cross-sectional Greek study. The study population consisted 
of primary care patients with moderate/severe persistent asthma for q6 months, treated 
according to new strategies, as deﬁned by GINA 2006, for q3 months. Data were 
collected during a single visit via a structured questionnaire. Moreover, participating 
patients completed 3 PROs. SATQ (treatment satisfaction), ACQ-5 (asthma control), 
and MiniAQLQ (QoL). RESULTS: 801 patients (M/F/Missing: 353/443/5, age 49.3 
o 15.5, 65.7% smokers) were enrolled from 104 ofﬁce-based physicians. 40.2% of 
patients reported being “very highly” satisﬁed, 31.9% “highly” satisﬁed, 15.9% 
“adequately” satisﬁed and 12% “moderately” to “not satisﬁed” with their treatment. 
Mean SATQ score was 5.4 o 0.9. 52.6% of patients reported an ACQ-5 a1.0 and 
64% a score of 1.5. Mean ACQ-5 score was 1.3 o 1.1, whereas mean MiniAQLQ 
score was 5.3 o 1.1. Good compliance (no treatment interruption within the previous 
6 months) was shown in 46.1% of patients. ACQ-5, SATQ and MiniAQLQ scores 
in patients with no treatment interruption as compared with those in patients with 
any treatment interruption were 1.2 o 1.2, 5.4 o 0.2, 5.5 o 0.9 vs 1.5 o 1.1, 5.2 o 1.0, 
5.3 o 0.9, respectively. CONCLUSIONS: Primary care asthma patients treated accord-
ing to the 2006 GINA guidelines in Greece, showed a relatively satisfactory asthma 
control and presented with good QoL and treatment satisfaction. However, there is 
room for improvement regarding disease control and treatment compliance. Com-
pliant patients demonstrated relatively better asthma control, QoL and treatment 
satisfaction.
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OBJECTIVES: To assess the health-related quality of life (HRQL) impacts of Xolair® 
(omalizumab), in routine Belgian clinical practice in patients with severe allergic 
asthma naïve to omalizumab. METHODS: A prospective open-label, single arm, 
observational, multicenter study with one year follow-up was conducted. Amongst 
other study outcomes (e.g. treatment effectiveness, exacerbation rate, drug consump-
tion, medical resources used, safety, . . .), HRQL was gauged using validated generic 
and disease speciﬁc instruments, i.e. the European Quality of Life Questionnaire 5 
Dimensions (EQ-5D) and the Asthma Quality of life Questionnaire (AQLQ), respec-
tively. The EQ-5D was administered at baseline and after 1 year, the AQLQ was 
administered at baseline, after 16 weeks of treatment and after one year to mimic 
what is legally required by Belgian authorities. For the EQ-5D, the Flemish value set 
was used to calculate utility scores. Minimally important differences for the EQ-5D 
and AQLQ were previously reported as 0.074–0.120 (depending on the disease con-
sidered) and 0.5, respectively. RESULTS: For this study, 160 patients were enrolled 
from 35 study centers geographically spread over Belgium. A marked improvement in 
EQ-5D was observed following treatment with omalizumab, at one year, a mean 
increase from baseline of 15.4 units for the visual analog scale and 0.13 for the utility 
score (n  71) were reported. These results were corroborated by the AQLQ results 
which showed an improvement from baseline in the total score of 1.37 points at 16 
weeks (n  142) and 1.80 points at one year (n  100). Improvements observed for 
the 4 AQLQ subscales were also consistent. CONCLUSIONS: This observational 
study showed signiﬁcant HRQL improvements, both in the EQ-5D and AQLQ, with 
the use of omalizumab in routine practice amongst patients with severe allergic 
asthma.
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More than 400,000 people in Denmark suffers from chronic obstructive lung disease 
(COPD) with implications for their quality of life (QoL). As a chronic disease reha-
bilitation of COPD is important. Today this is the responsibility of the health care 
centres in the municipalities in cooperation with the general practitioners and hospi-
tals. OBJECTIVES: Investigate the improvement in quality of life for the COPD 
patients entering the health care centres for rehabilitation. METHODS: 22 Danish 
municipality health care centres (20% of Danish municipalities and 50% of current 
rehabilitation centres) participated in the project. Each centre had their own rehabilita-
tion strategy and included COPD patients undergoing rehabilitation in the project. 
QoL was one focus for measurement of the effect of the rehabilitation. The 15D 
instrument was chosen due to its high correlation with typical COPD symptoms, pul-
monary function and test capacity, and studies has found it sensitive in COPD. Besides 
QoL other effect indicators were 6 min. walking distance and shuttle walk, as well as 
demographic data was recorded in a database. Data was measured before and after 
rehabilitation in a longitudinal cohort design to measure change in outcome due to 
rehabilitation. RESULTS: 396 COPD patients completing rehabilitation (40% males, 
mean age of 68 years, BMI 25.8, 29% current smokers, 65% ex-smokers, and 40 
pack years of smoking) were included. Comparing pre- and post-rehabilitation the 
QALY value measured with the 15D instrument increased from 0.8 to 0.84 (p  0.01) 
having rehabilitation. This was also regarded as a clinical signiﬁcant change (0.03). 
Comparable with the improvement in quality of life both 6 min. walk and shuttle 
walk improved for the average patient comparing pre- and post-rehabilitation. CON-
CLUSIONS: The study shows that rehabilitation activities of COPD patients in the 
health care centres in Danish municipalities is important as it signiﬁcantly improves 
patients quality of life.
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OBJECTIVES: The aim of this study was to analyse the association between tobacco            
consumption and Health-Related Quality of Life (HRQoL) in a general population 
on the basis of a representative panel dataset in Germany. METHODS: The analysis  
was designed as a cross-sectional study using the data of the “German Socio-Economic 
Panel Study” (SOEP) for the year 2006. The HRQoL was measured by the SF-12v2 
(SOEP-Version with norm-based scores for all dimensions). For each of the eight 
subscores and both composite scores a separate multivariate linear regression analysis 
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was conducted. RESULTS: Overall, 20,488 cases were included in the analysis. After         
the adjustment for age, sex, body-mass-index and duration of education there is a 
statistically signiﬁcant association between consumption of tobacco and HRQoL in 
all subscores as well as both composite scores of the SF-12. The regression coefﬁcients 
for current smoking (all non-smokers as reference group) are relatively small with 
0.68 (role physical) to 1.35 (general health) points for physical domains and 
between 0.58 (vitality) and 1.47 (mental health) points for mental domains. These 
differences increase considerable for elderly persons (age of 50 or older, N  9830) 
with 1.274 (role physical) to 1.87 (general health) points for physical and 0.953 
(vitality) to 1.682 (social functioning) for mental scales. Equally, there is a strong 
statistical association between the current amount of smoking (per 10 cigarettes per 
day) and HRQoL (0.342 to 0.858 for physical and 0.47 to 1.07 for mental 
domains, N  5560). CONCLUSIONS: In particular, the ﬁndings are limited by the        
inconclusive causality direction for smoking and mental health. However, these results 
conﬁrm the existing evidence concerning the negative association between smoking 
status or smoking intensity and HRQoL in a general population.
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OBJECTIVES: To validate the Spanish version of the speciﬁc questionnaire “COPD 
and asthma sleep impact scale (CASIS)” which measures the impact of sleep quality 
in patients with COPD on their HRQoL. METHODS: Observational, prospective, 
multicenter study in patients with moderate/severe COPD. Data were collected at 
inclusion and at day 15, including the Spanish version of CASIS (7 items, range: 7 
best–35 worst) and the “gold standard” Saint George Respiratory Questionnaire 
(SGRQ). Additionally, socio-demographics, clinical data and one item about self-
 perceived change in health status between visits were recorded. Feasibility, validity, 
reliability (internal consistency, test-retest) and responsiveness to change of the CASIS 
Spanish version were evaluated. RESULTS: A total of 142 patients were included, 
87.1% males, mean age (SD) was 67.4(8.2) years, 52.7% with primary studies, 75% 
former smokers, FEV1 (%)  48.5%, (SD  13.3), 51.3% stage II, 37.6% stage III and 
11.1% stage IV. Mean (SD) score in CASIS was 18.5(6.5). CASIS questionnaire 
showed low levels of absent information: the mean number of items not responded 
per patient was 0.1, and no item accumulated more than 1 missing response. Ceilling 
effects of CASIS (proportion of patients accumulated in the maximum possible score) 
were null, and ﬂoor effects (proportion of patients accumulated in the minimum pos-
sible score) were 7.5%. CASIS showed low internal consistency (Cronbach’s alpha 
0.50) but an excellent test-retest reliability among patients who reported subjective 
stability in their health status (inter-class correlation coefﬁcient  0.88). Correlations 
between CASIS and SGRQ global scores were high (0.71) and correlations between 
CASIS and SGRQ dimensions were moderate to high (0.62 to 0.69). Signiﬁcant dif-
ferences (p  0.01) in LCOPD were observed in exacerbated patients who reported 
an improvement, with a high effect size (0.90). CONCLUSIONS: According to pre-
liminary results, Spanish version of CASIS showed satisfactory psychometric proper-
ties in terms of feasibility, validity, reliability and responsiveness to change.
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OBJECTIVES: It is hypothesised that cough and/or sputum symptoms have a negative 
impact on health-related quality of life (HRQoL) in chronic obstructive pulmonary 
disease (COPD). This study assessed the impact of these symptoms on HRQoL in 396 
COPD patients. METHODS: Data were drawn from the Respiratory Adelphi Disease 
Speciﬁc Programme conducted in France, Germany, Italy, Spain, the UK and the USA 
in 2008. Information collected included physicians’ perceptions of symptom severity. 
Patients were invited to ﬁll out a questionnaire that included EQ-5D. Variables anal-
ysed were age, gender, body mass index, breathlessness, smoking status, co-morbidi-
ties (heart-related and anxiety/depression), compliance, most recent forced expiratory 
volume in 1 second (FEV1, if available) and country of origin. Due to a highly skewed 
EQ-5D distribution, three regression methods were applied (Tobit, OLS and GLM) 
to assess the impact of these variables on HRQoL. Final models derived included sta-
tistically signiﬁcant variables only (p  0.05). RESULTS: Using all three methods, 
cough and/or sputum were signiﬁcant predictors of worse HRQoL compared with 
COPD patients not experiencing these symptoms. FEV1 was only a signiﬁcant predic-
tor of better HRQoL in the Tobit approach. In this model, patients with moderate or 
severe cough and/or sputum symptoms presented with worse HRQoL compared with 
the wider COPD population (-0.09, 95% CI 0.14, 0.04). FEV1 values 30–50% 
predicted are associated with higher EQ-5D (0.006, p  0.05). However, no further 
signiﬁcant impact was present at FEV1 50% predicted. In the Tobit model, patients 
not viewed as fully compliant with the current drug regimen were also associated with 
worse EQ-5D (0.09, p  0.05). Similar statistically signiﬁcant variables were observed 
using the GLM and OLS models. CONCLUSIONS: Presence and severity of cough 
and/or sputum in COPD has a marked association with worse HRQoL, independent 
of FEV1 measurements. These results indicate unmet therapeutic needs in this 
population.
PRS41
VALIDATION OF THE SPANISH VERSION OF THE “LIVING WITH 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (LCOPD)” 
QUESTIONNAIRE
Lahoz R1, Galera J1, Lleonart M1, Miravitlles M2
1Novartis Pharmaceuticals, Barcelona, Spain, 2Hospital Clínic, Barcelona, Spain
OBJECTIVES: To validate the Spanish version of the quality of life (QoL) speciﬁc 
questionnaire for patients with COPD “Living with Chronic Obstructive Pulmonary 
Disease” (LCOPD). METHODS: Observational, prospective, multicenter study in a 
sample of patients with moderate/severe COPD. Data were collected at inclusion and 
at day 15, including the Spanish version of LCOPD (22 items, range: 22 worst—44 
best) and the “gold standard” Saint George Respiratory Questionnaire (SGRQ). 
Additionally, socio-demographics, clinical data and one item about self-perceived 
change in health status between visits were recorded. Feasibility, validity, reliability 
(internal consistency, test-retest) and responsiveness to change of the LCOPD Spanish 
version were evaluated. RESULTS: A total of 142 patients were included, 87.1% 
males, mean age (SD) was 67.4 (8.2) years, 52.7% with primary studies, 75% former 
smokers, FEV1 (%)  48.5%, (SD  13.3), 51.3% stage II, 37.6% stage III and 11.1% 
stage IV. Mean (SD) score in LCOPD was 33.0 (6.7). LCOPD questionnaire showed 
low levels of absent information: the mean number of items not responded per patient 
was 0.1, and no item accumulated more than 1 missing response. Floor and ceiling 
effects of LCOPD (proportion of patients accumulated in the minimum and maximum 
possible scores, respectively), were low (6%). LCOPD showed satisfactory levels of 
reliability: high internal consistency (Cronbach’s alpha  0.94) and excellent test-retest 
reliability among patients who reported subjective stability in their health status (inter-
class correlation coefﬁcient  0.92, p  0.001). Correlations between LCOPD and 
SGRQ global scores were very high (0.85), and correlations between LCOPD and 
SGRQ dimensions were moderate to high (0.60 to 0.87). Signiﬁcant differences (p  
0.05) in LCOPD were observed in exacerbated patients who reported an improvement, 
with a small to moderate effect size (0.31). CONCLUSIONS: According to preliminary 
results, Spanish version of LCOPD showed satisfactory psychometric properties in 
terms of feasibility, validity, reliability and responsiveness to change.
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OBJECTIVES: To validate the Spanish version of the health speciﬁc questionnaire to 
evaluate the impact of fatigue on patients with COPD “COPD and asthma fatigue 
scale (CAFS)”. METHODS: Observational, prospective, multicenter study in a sample 
of patients with moderate/severe COPD. Data were collected at inclusion and at day 
15, including the Spanish version of CAFS (12 items, range: 12 best–60 worst) and 
the “gold standard” Saint George Respiratory Questionnaire (SGRQ). Additionally, 
socio-demographics, clinical data and one item about self-perceived change in health 
status between visits were recorded. Feasibility, validity, reliability (internal consis-
tency, test-retest) and responsiveness to change of the CAFS Spanish version were 
evaluated. RESULTS: A total of 142 patients were included, 87.1% males, mean age 
(SD) was 67.4 (8.2) years, 52.7% with primary studies, 75% former smokers, FEV1 
(%)  48.5%, (SD  13.3), 51.3% stage II, 37.6% stage III and 11.1% stage IV. Mean 
(SD) score in CAFS was 36.7 (12.1). CAFS questionnaire showed low levels of absent 
information: the mean number of items not responded per patient was 0.1, and no 
item accumulated more than 1 missing response. Floor and ceiling effects of CAFS 
(proportion of patients accumulated in the minimum and maximum possible scores, 
respectively), were low (2%). CAFS showed satisfactory levels of reliability: high 
internal consistency (Cronbach’s alpha  0.88) and excellent test-retest reliability 
among patients who reported subjective stability in their health status (inter-class 
correlation coefﬁcient  0.85). Correlations between CAFS and SGRQ global scores 
were high (0.79), such as the correlations between CAFS and SGRQ dimensions (0.63 
to 0.74). Signiﬁcant differences (p  0.01) in LCOPD were observed in exacerbated 
patients who reported an improvement, with a high effect size (0.90). CONCLU-
SIONS: According to preliminary results, Spanish version of CAFS showed satisfactory 
psychometric properties in terms of feasibility, validity, reliability and responsiveness 
to change.
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OBJECTIVES: The aim of this study was to determine the reliability and validity of 
the Smoker Complaint Scale for the Turkish population. METHODS: The research 
was conducted in the university students. For pretest study forty students were chosen 
as a sampling group. After the assessment of the results, the Smoker Complaint Scale 
was applied to 250 students who quit smoking. Of the students are 54% female and 
46% male. The original instrument was translated into Turkish and then translated 
back into English by two independent translators. For psychometric measures, a small 
sample was used to check the initial comprehension and factibility. Cronbach’s Alfa 
was used to assess reliability and factor analysis to assess dimensionality. The 
EuroQol-5D was used for concurrent validity. RESULTS: The internal consistency 
coefﬁcient (Cronbach’s alpha) of SCS was 0.912. Factor analysis of the scale revealed 
that it was composed of 5 factors with Eigenvalues 1.0, accounting for 77.9% of the 
total variance. All the items of the Turkish SCS had a factor load ranging from 0.587 
